Skip to main content
Top

Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis

Published in:

Abstract

Radiologically isolated syndrome (RIS) is the earliest stage in the disease continuum of multiple sclerosis (MS). RIS is discovered incidentally in individuals who are asymptomatic but have typical lesions in the brain and/or spinal cord suggestive of demyelination. The 2009 and revised 2023 RIS criteria were developed for diagnosis. Presymptomatic individuals who fulfill the 2009 RIS criteria by having 3–4 of 4 dissemination in space McDonald 2005 MS criteria are still diagnosed with RIS using the revised 2023 RIS criteria. In presymptomatic individuals who do not fulfill the 2009 RIS criteria, the revised 2023 RIS criteria target to secure an accurate and timely diagnosis: In addition to (a) having one lesion in two of four locations (periventricular, juxtacortical/cortical, infratentorial, spinal cord), (b) two of three features (spinal cord lesion, cerebrospinal fluid (CSF)-restricted oligoclonal bands, and new T2 or gadolinium-enhancing lesion) should be fulfilled. Among laboratory biomarkers, CSF kappa-free light chain can also increase diagnostic accuracy. Once the diagnosis is confirmed, the established risk factors, including demographics, imaging, and laboratory biomarkers, should be evaluated for symptomatic MS transition and prognosis. Younger age, male sex, increased neurofilament-light chain, CSF abnormality, and the presence of infratentorial, spinal cord, or gadolinium-enhancing lesions on imaging are the main risk factors for transition to symptomatic MS. Two randomized clinical trials showed significant efficacy of disease-modifying treatments in delaying or preventing the development of the first clinical event in RIS. However, because some individuals remain as RIS, it is crucial to identify the individuals with a higher number of risk factors to optimize disease outcomes by early intervention while minimizing adverse events. Discussing each RIS case with an expert MS team is recommended because there is still a lack of clinical guidelines to improve care, counseling, and surveillance.
Title
Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis
Authors
Burcu Zeydan
Christina J. Azevedo
Naila Makhani
Mikael Cohen
Melih Tutuncu
Eric Thouvenot
Aksel Siva
Darin T. Okuda
Orhun H. Kantarci
Christine Lebrun-Frenay
Publication date
16-09-2024
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 12/2024
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-024-01117-9
This content is only visible if you are logged in and have the appropriate permissions.

Mini masterclass: enhancing outcomes in LGS (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)

These six bite-sized videos will equip you with insights into the pathophysiological processes underlying Lennox–Gastaut syndrome, the burden on patients and caregivers, and opportunities to increase diagnostic accuracy and optimize treatment strategies.

Independent Medical Education Grant:
  • Jazz Pharmaceuticals
Watch now TODO (Link opens in a new window)

Keynote webinar | Spotlight on functional neurological disorder

FND perplexes and frustrates patients and physicians alike. Limited knowledge and insufficient awareness delays diagnosis and treatment, and many patients feel misunderstood and stigmatized. How can you recognize FND and what are the treatment options?

Prof. Mark Edwards
Watch now
Video
Image Credits
Enchancing Lennox-Gastaut Syndrome program image/© Springer Health+ IME, Human brain illustration/© (M) CHRISTOPH BURGSTEDT / SCIENCE PHOTO LIBRARY / Getty Images